December 8, 2025BloodOpen Access

Cladribine, idarubicin, and AraC (CLIA) combined with a FLT3 inhibitor in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A pooled analysis of prospective trials

View Full Paper

Ask AI

Bookmark

83% of patients achieved complete remission, indicating treatment effectiveness in FLT3-mutated acute myeloid leukemia.
Patients received an average of 2 cycles of intense chemotherapy, with 88% achieving measurable residual disease negativity.
Observational analysis across multiple trials revealed that long-term overall survival exceeded 75% for patients with co-mutations such as DNMT3A.
Findings highlight the survival benefits of the CLIA regimen combined with sorafenib, noting common adverse events.

Discussion

No takes yet. Share an insight, caveat, or question.

Pooled analysis demonstrates high complete remission in FLT3-mutated acute myeloid leukemia with co-mutations, implying improved long-term survival.

Daver et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Pooled analysis demonstrates high complete remission in FLT3-mutated acute myeloid leukemia with co-mutations, implying improved long-term survival.